# A Trial to Evaluate the Efficacy, Safety, and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder

> **NCT03605836** · PHASE3 · COMPLETED · sponsor: **Otsuka Pharmaceutical Development & Commercialization, Inc.** · enrollment: 590 (actual)

## Conditions studied

- Attention Deficit Disorder
- Attention Deficit Hyperactivity Disorder

## Interventions

- **DRUG:** Centanafadine SR
- **OTHER:** Placebo
- **DRUG:** Centanafadine SR

## Key facts

- **NCT ID:** NCT03605836
- **Lead sponsor:** Otsuka Pharmaceutical Development & Commercialization, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-16
- **Primary completion:** 2020-05-14
- **Final completion:** 2020-05-14
- **Target enrollment:** 590 (ACTUAL)
- **Last updated:** 2021-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03605836

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03605836, "A Trial to Evaluate the Efficacy, Safety, and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03605836. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*